PA
Perceptive Advisors Portfolio holdings
AUM
$2.67B
This Quarter Return
+30.71%
1 Year Return
+73.17%
3 Year Return
+837.18%
5 Year Return
+928.4%
10 Year Return
+11,818.45%
AUM
$4.66B
AUM Growth
+$4.66B
(+12%)
Cap. Flow
-$219M
Cap. Flow
% of AUM
-4.69%
Top 10 Holdings %
Top 10 Hldgs %
46.73%
Holding
123
New
13
Increased
23
Reduced
25
Closed
18
Top Buys
| 1 |
VRNA
Verona Pharma
VRNA
|
$112M |
| 2 |
Viking Therapeutics
VKTX
|
$62M |
| 3 |
argenx
ARGX
|
$56M |
| 4 |
Nuvalent
NUVL
|
$44M |
| 5 |
CNTA
Centessa Pharmaceuticals
CNTA
|
$37.6M |
Top Sells
| 1 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
$441M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
$74.1M |
| 3 |
Neurocrine Biosciences
NBIX
|
$50.4M |
| 4 |
Natera
NTRA
|
$39.4M |
| 5 |
Crinetics Pharmaceuticals
CRNX
|
$38.4M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Edgewise Therapeutics
EWTX
$1.51B
| $62.2M | 1.32% | 2,330,294 +473,877 | +26% | +$12.6M |
|
27
Protagonist Therapeutics
PTGX
$3.67B
| $61.9M | 1.31% | 1,374,563 +105,828 | +8% | +$4.76M |
|
28
MeiraGTx Holdings
MGTX
$587M
| $52.4M | 1.11% | 12,581,103 +1,250,000 | +11% | +$5.21M |
|
29
Aldeyra Therapeutics
ALDX
$351M
| $50M | 1.06% | 9,275,851 | – | – |
|
30
Akero Therapeutics
AKRO
$3.74B
| $49.2M | 1.04% | 1,714,806 +214,909 | +14% | +$6.17M |
|
31
Solid Biosciences
SLDB
$427M
| $48.1M | 1.02% | 6,906,646 | – | – |
|
32
Tarsus Pharmaceuticals
TARS
$2.47B
| $42.6M | 0.9% | 1,296,416 | – | – |
|
33
Acrivon Therapeutics
ACRV
$42.2M
| $37.5M | 0.79% | 5,360,858 | – | – |
|
|
34
Crinetics Pharmaceuticals
CRNX
$2.92B
| $37M | 0.78% | 724,698 -751,505 | -51% | -$38.4M |
|
35
Nautilus Biotechnolgy
NAUT
$85.9M
| $35.9M | 0.76% | 12,594,211 | – | – |
|
36
Celcuity
CELC
$2.17B
| $35.2M | 0.75% | 2,362,279 | – | – |
|
37
Insulet
PODD
$23.9B
| $33.1M | 0.7% | +142,269 | New | +$33.1M |
|
|
ORKA
38
Oruka Therapeutics, Inc. Common Stock
ORKA
$554M
| $30.3M | 0.64% | +1,235,187 | New | +$30.3M |
|
|
CTNM
39
Contineum Therapeutics
CTNM
$293M
| $29M | 0.61% | 1,516,668 -50,000 | -3% | -$957K |
|
40
Ocular Therapeutix
OCUL
$2.12B
| $28.9M | 0.61% | 3,324,468 | – | – |
|
41
Intuitive Surgical
ISRG
$170B
| $28.6M | 0.6% | 58,119 -3,681 | -6% | -$1.81M |
|
|
42
Natera
NTRA
$23.1B
| $27.9M | 0.59% | 220,000 -310,000 | -58% | -$39.4M |
|
43
CG Oncology
CGON
$2.04B
| $27.7M | 0.59% | 733,695 | – | – |
|
44
Zymeworks
ZYME
$1.12B
| $27.4M | 0.58% | 2,180,020 +512,309 | +31% | +$6.43M |
|
45
Dyne Therapeutics
DYN
$1.92B
| $25.8M | 0.55% | +718,144 | New | +$25.8M |
|
|
ADGM
46
Adagio Medical Holdings, Inc Common Stock
ADGM
$24.8M
| $25.3M | 0.54% | +9,812,419 | New | +$25.3M |
|
47
Arvinas
ARVN
$568M
| $25.3M | 0.54% | 1,027,749 | – | – |
|
48
Procept Biorobotics
PRCT
$2.23B
| $25.3M | 0.54% | 315,659 +105,000 | +50% | +$8.41M |
|
|
49
Neurocrine Biosciences
NBIX
$13.8B
| $24.5M | 0.52% | 212,228 -437,681 | -67% | -$50.4M |
|
50
Orchestra BioMed
OBIO
$147M
| $23.6M | 0.5% | 4,592,556 +2,046,675 | +80% | +$10.5M |
|